

Table 1 Revised base case cost-effectiveness analysis, incorporating corrections and amendments identified by the ERG

	BSC		Ipilimumab		Incremental		ICER
	Cost per patient	QALYs per patient	Cost per patient	QALYs per patient	Cost per patient	QALYs per patient	Cost per QALY gained
Manufacturer's base case analysis	£12,837	1.0077	£96,188	2.3800	£83,351	1.3723	£60,737
Correct background mortality logic error	£12,079	0.8790	£96,382	2.4127	£84,303	1.5337	£54,966
Correct AE costs logic error	£12,837	1.0077	£94,715	2.3800	£81,878	1.3723	£59,664
Amend age-adjustment to utility values	£12,837	1.0002	£96,188	2.3491	£83,351	1.3489	£61,791
ERG estimate of ipilimumab costs	£12,837	1.0077	£95,416	2.3800	£82,579	1.3723	£60,175
ERG revised base case analysis (all four changes)	£12,079	0.8743	£94,137	2.3811	£82,059	1.5067	£54,462
ERG revised base case analysis + exploratory survival modelling	£11,027	0.7043	£88,618	1.5066	£77,591	0.8022	£96,717